Breast Cancer Special Issue

For many patients with early-stage breast cancer, these drugs provide a significant boost to disease-free survival.

Laura Yeager talks about her journey with breast cancer, from the fearful thoughts to the free food at chemotherapy.

Biosimilars are changing the field — and the price — of cancer treatment, though some questions still remain.

Extending hormonal therapy to 10 years has been found to reduce recurrence in HR-positive breast cancer.

In some cases, genomic blood analysis may be effective enough to replace cancer biopsies.

Biosimilars are likely to rival name-brand treatments for breast and other cancers, and the competition could drive prices down.

Joining cancer registries can help patients and the larger oncology community.

Herceptin has improved survival for women with HER2-positive breast cancer. Now, scientists are exploring ways to mitigate the heart problems the drug can cause.

Excitement is growing over new strategies for treating or avoiding peripheral neuropathy in patients with cancer.

Once considered “immunologically silent,” breast cancer may actually respond to immunotherapy.